Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 18 04:00PM ET
14.72
Dollar change
-0.02
Percentage change
-0.14
%
IndexRUT P/E- EPS (ttm)-0.08 Insider Own1.82% Shs Outstand14.35M Perf Week0.41%
Market Cap213.73M Forward P/E- EPS next Y- Insider Trans- Shs Float14.25M Perf Month0.14%
Income-1.18M PEG- EPS next Q- Inst Own64.18% Short Float5.43% Perf Quarter11.35%
Sales0.00M P/S- EPS this Y- Inst Trans-0.55% Short Ratio7.70 Perf Half Y20.26%
Book/sh1.31 P/B11.27 EPS next Y- ROA-6.05% Short Interest0.77M Perf Year25.17%
Cash/sh1.30 P/C11.32 EPS next 5Y5.60% ROE-6.22% 52W Range11.40 - 15.89 Perf YTD9.77%
Dividend Est.- P/FCF- EPS past 5Y56.22% ROI-6.30% 52W High-7.36% Beta1.43
Dividend TTM- Quick Ratio43.50 Sales past 5Y0.00% Gross Margin- 52W Low29.12% ATR (14)0.17
Dividend Ex-DateDec 13, 2019 Current Ratio43.50 EPS Y/Y TTM27.67% Oper. Margin0.00% RSI (14)63.84 Volatility0.61% 0.69%
Employees- Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom4.00 Target Price4.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q53.22% Payout- Rel Volume0.92 Prev Close14.74
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsMar 07 AMC Avg Volume100.47K Price14.72
SMA200.12% SMA505.46% SMA20015.16% Trades Volume91,728 Change-0.14%
Date Action Analyst Rating Change Price Target Change
Oct-07-16Downgrade JP Morgan Overweight → Neutral
May-27-16Initiated Robert W. Baird Neutral $8
Dec-23-15Reiterated Mizuho Buy $16 → $13
Oct-27-15Reiterated Oppenheimer Outperform $13 → $15
Apr-21-15Reiterated Mizuho Buy $13 → $16
Oct-10-14Resumed Oppenheimer Outperform $9 → $11
Jul-08-14Resumed Brean Capital Buy $16
Jun-20-14Reiterated Oppenheimer Outperform $10 → $8.50
Aug-09-13Reiterated Oppenheimer Outperform $12 → $10
Jun-25-13Initiated Mizuho Buy $12
Mar-08-24 08:51AM
Mar-07-24 04:30PM
Feb-13-24 04:18PM
Dec-29-23 01:48PM
Nov-02-23 04:30PM
07:02AM Loading…
Aug-15-23 07:02AM
Aug-03-23 04:30PM
Jul-03-23 08:24AM
May-04-23 05:00PM
Apr-19-23 07:02AM
Mar-09-23 04:40PM
Jan-23-23 08:44AM
Dec-28-22 10:15PM
Dec-13-22 06:44AM
Dec-05-22 09:00AM
06:56AM Loading…
Nov-17-22 06:56AM
Nov-16-22 11:28AM
Nov-10-22 05:11AM
Nov-09-22 10:13AM
09:04AM
Nov-03-22 04:45PM
Aug-16-22 08:11AM
Aug-04-22 05:00PM
Aug-03-22 11:49AM
08:30AM
Jul-06-22 07:07AM
May-05-22 04:30PM
Mar-09-22 04:30PM
Jan-27-22 04:48AM
Dec-06-21 07:22AM
05:00PM Loading…
Nov-04-21 05:00PM
Sep-06-21 09:50AM
Aug-05-21 04:30PM
Jun-08-21 05:31AM
Jun-07-21 02:10PM
May-28-21 08:00AM
Mar-10-21 06:00PM
Dec-10-20 02:10AM
Dec-03-20 07:46AM
Nov-29-20 12:12PM
Nov-05-20 08:20AM
Aug-07-20 08:20AM
Aug-05-20 08:33AM
May-07-20 06:10PM
Apr-02-20 08:30AM
Feb-07-20 11:14AM
Dec-22-19 07:44PM
Dec-03-19 09:15AM
08:45AM
Oct-28-19 06:04AM
Sep-24-19 04:45PM
Sep-19-19 03:23PM
09:00AM
Aug-26-19 11:27AM
09:00AM
Aug-22-19 08:30AM
Aug-16-19 09:15AM
Jul-25-19 08:30AM
May-31-19 07:34AM
06:21AM
May-30-19 04:05PM
May-10-19 07:30AM
May-06-19 01:46PM
May-03-19 05:43PM
Apr-18-19 03:07PM
Apr-16-19 04:15PM
Apr-12-19 01:57PM
Apr-09-19 05:50PM
Apr-08-19 10:12AM
Apr-05-19 08:29AM
07:48AM
Apr-04-19 05:58PM
04:15PM
Mar-07-19 09:06AM
Mar-06-19 07:00AM
Feb-12-19 07:35AM
Feb-11-19 09:39AM
Jan-28-19 10:19PM
Dec-10-18 05:00PM
Nov-09-18 10:31AM
08:45AM
Nov-08-18 10:17AM
Nov-07-18 06:45AM
Nov-06-18 01:44PM
Nov-05-18 07:55AM
Oct-31-18 04:05PM
Oct-24-18 11:19AM
Oct-19-18 10:48AM
07:46AM
06:00AM
Oct-16-18 07:30AM
Oct-11-18 05:16PM
Sep-20-18 07:00AM
Sep-06-18 10:35AM
06:50AM
Sep-05-18 12:06PM
Sep-04-18 10:07AM
Aug-16-18 08:00AM
Aug-08-18 10:20AM
Aug-07-18 08:18AM
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Andersen EricDirectorDec 28 '23Buy13.3585711,441534,008Dec 28 04:05 PM
Andersen EricDirectorDec 26 '23Buy13.1548,693640,313533,151Dec 28 04:05 PM
Andersen EricDirectorDec 07 '23Buy12.85101,0501,298,4721,735,600Dec 11 04:05 PM
Andersen EricDirectorNov 17 '23Buy12.503003,7501,659,216Nov 20 06:59 PM
Andersen EricDirectorNov 14 '23Buy12.5050,170627,1251,658,981Nov 16 05:09 PM
Andersen EricDirectorNov 09 '23Buy12.199,975121,6181,577,704Nov 13 04:05 PM
Andersen EricDirectorNov 08 '23Buy12.1313,823167,7011,569,894Nov 13 04:05 PM
CROCKER GARY LSee RemarksAug 11 '23Buy12.432,00024,865133,105Aug 14 04:06 PM
CROCKER GARY LSee RemarksAug 10 '23Buy12.522,00025,039133,105Aug 14 04:06 PM
Andersen EricDirectorAug 08 '23Buy12.0087,0571,044,3271,565,111Aug 09 04:06 PM
Andersen EricDirectorAug 07 '23Buy12.00134,4931,614,4141,496,680Aug 09 04:06 PM
Andersen EricDirectorMar 21 '23Buy11.52160,5901,849,9971,412,044Mar 22 04:06 PM